MCL1 and cancer: Therapeutic strategies such as the use of pemetrexed, an antifolate chemotherapy drug, have shown promise in preclinical and clinical settings by disrupting the Noxa-Usp9x-Mcl-1 pathway, highlighting the significant potential of Mcl-1-targeted interventions to improve cancer treatment outcomes [62].